With strong commitment on using iPSC technology to study CNS diseases, scientists at XCell have built three core competencies, iPSC generation, iPSC engineering, and directed differentiation of iPSC into neuronal and glial cells. In collaboration with scientists at Sigma-Aldrich and NIH, we have successfully made more than 20 engineered iPSC lines in less than 12 months and have differentiated these iPSC lines into various neural lineage cells. In addition, we have developed a suite of bioassays (e.g. cell viability assay and luciferase assay) using neural stem cells, neurons, and astrocytes. With a proven track record, our custom services offer high quality, fast turnaround time, and competitive pricing. Currently, we provide the following services:
